Coronavirus (COVID-19)
Learn more
March 13, 2013
Location: The Hospital of Central Connecticut
An Open-Label, Randomized, Phase IIIB Trial Evaluating The Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After First-Line Treatment with Bevacizumab Plus a Platinum Doublet-Containing Chemotherapy.
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.